Note: Ingredients listed on restricted chemical lists
EC/CAS
200-317-6/57-15-8
Name of the chemical
Chlorobutanol
Concentration
≤0.5%
EC/CAS
200-098-7/51-43-4
Name of the chemical
Epinephrine (INN)
Concentration
≤0.1%
General Information
Version
1.1.0
Revision date
2015-05-01
Product name
Adrenalin
Product Synonyms
Epinephrine chloride solution; For epinephrine: 4-[1-hydroxy-2-(methylamino)ethyl]1,2 benzenediol
Chemical name
Mixture - contains benzenediol derivative
1.2.1 Relevant identified uses
Bulk formulated pharmaceutical mixture/Formulated pharmaceutical product of the substance or packaged in final form for patient use; indicated for the emergency treatment of mixture and uses severe acute allergic reactions, asthma, and chronic pulmonary disease
Emergency telephone
+1 (800) 424-9300, +1 (703) 527-3887
Icons in SDS
Company Information
company name
drugsafety@parpharm.com
e-mail address of the competent person responsible for the Safety Data Sheet
drugsafety@parpharm.com
GHS Information
Signal word
None required
Section 2
SECTION 2: Hazards identification
GHS Classification Classification of the substance or mixture Drugs in the finished state and intended for the final user are not subject to labeling in the US, EU or Canada. Please consult the prescribing/packaging information. The classification and labeling listed below is for bulk Epinephrine Solution Regulation (EC) 1272/ 2008 [GHS] Not classified Directive 67/548/EEC Not classified or 1999/45/EC
2.2 Label elements
CLP/GHS hazard None required
Signal word
None required CLP/GHS hazard None required US Hazard overview Note None required This mixture does not meet criteria for classification according to directive 1999/
Hazard statements
CLP/GHS None required
Precautionary statements
EU symbol/indication of danger None required Risk (R) Phrase(s) None required None required
2.3 Other hazards
Epinephrine (i.e., adrenaline) is an endogenous neurotransmitter hormone and its primary effects are vasoconstriction, cardiac stimulation, and smooth muscle relaxation. The most common adverse effects reported with therapeutic use include transient/moderate anxiety, feelings of over stimulation, restlessness, headache, tremor, weakness, shakiness, dizziness, sweating, increased heart rate, palpitations, paleness, nausea, vomiting, and difficulty breathing. Other symptoms, such as high blood pressure, cardiac arrhythmias, and cerebral bleeding, have occurred. As epinephrine can cross the placenta, it may adversely affect the fetus (e.g., reduce fetal oxygen levels due to constriction of blood vessels).
2.1 Classification of the substance or mixture
Drugs in the finished state and intended for the final user are not subject to substance or mixture
